Navigation Links
Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis
Date:6/16/2010

s_gi(s_account);s.linkTrackVars='prop5,eVar3,prop15';s.prop5='External Link';s.eVar3=s.prop5;s.prop15='96457079';s.tl(this,'o','ExternalLink');" target='_blank' href="http://www.abbott.com/">www.abbott.com

Neurocrine Biosciences Forward Looking Statement

In addition to historical facts, this press release may contain forward-looking statements that involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with Neurocrine's business and finances in general, as well as risks and uncertainties associated with the Company's GnRH program and Company overall. Specifically, the risks and uncertainties the Company faces with respect to the Company's GnRH program include, but are not limited to, risk that the elagolix clinical trials will fail to demonstrate that elagolix is safe and effective; risk that elagolix will not proceed to Phase III clinical trials; risk associated with the Company's dependence on Abbott for Phase III development, commercial manufacturing and marketing and sales activities. With respect to its pipeline overall, the Company faces risk that it will be unable to raise additional funding required to complete development of all of its product candidates; risk relating to the Company's dependence on contract manufacturers for clinical drug supply; risks associated with the Company's dependence on corporate collaborators for commercial manufacturing and marketing and sales activities; uncertainties relating to patent protection and intellectual property rights of third parties; risks and uncertainties relating to competitive products and technological changes that may limit demand for the Company's products; and the other risks described in the Company's report on Form 10-K for the year ended December 31,
'/>"/>

SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Neurocrine Biosciences Announces Conference Call and Webcast on Worldwide Agreement With Abbott on Elagolix
2. Abbott to Become No. 1 Pharmaceutical Company in India with Acquisition of Piramals Healthcare Solutions Business
3. Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech
4. Updated Abbott Statement: To Help Respond to Growing Health Crisis, Abbott Increases Aid to $2.5 Million for Haiti Relief and Recovery Efforts
5. Abbott Hosts Conference Call for Third-Quarter Earnings
6. Abbott Declares 343rd Consecutive Quarterly Dividend
7. Abbott Wins Top Honor in Wall Street Journal Technology Innovation Awards
8. Abbott Announces Approval in China for Next-Generation XIENCE V(R) Drug Eluting Stent
9. Abbott to Acquire Evalve, Inc., a Leader in Minimally Invasive Cardiac Valve Repair Technology
10. Abbott Expands XIENCE V(R) USA Trial to Enroll Patients into Landmark Dual Anti-Platelet Therapy (DAPT) Trial
11. Abbott HIV Test Demonstrates Earlier Disease Detection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... NEW YORK , June 30, 2015  The Dr. ... is now offering a full suite of new ... who,ve had a biopsy, for diagnosing prostate cancer. ... a range of genetic tests for assessing the risk and ... "We,re very excited to now offer these ...
(Date:6/30/2015)... , ... June 30, 2015 , ... ... digital media company, launched “Cannavoices,” an unprecedented digital video and broadcast initiative. Produced ... also the most dynamic collection of legal medical cannabis stories ever assembled. ...
(Date:6/29/2015)... and Manhattan, KS (PRWEB) , ... June 29, ... ... acquired US PATENT 7736892 B2. Under the terms of the agreement, MediVet will ... Cord Matrix Stem Cells (UCMSCs). MB-007 is currently in pre-clinical development as a ...
(Date:6/29/2015)... 29, 2015  AACC, a global scientific and ... laboratory medicine, is pleased to announce that the ... , has increased to 7.9 in the 2014 ... Clinical Chemistry in the top 3% ... influence of the research it publishes on laboratory ...
Breaking Biology Technology:New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 2New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 3New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 4New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 5Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 2Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 3MediVet Biologics Acquires Exclusive Patent License from Kansas State University 2MediVet Biologics Acquires Exclusive Patent License from Kansas State University 3AACC's Journal, Clinical Chemistry, Continues to Have Significant Impact on Medical Testing, Healthcare 2AACC's Journal, Clinical Chemistry, Continues to Have Significant Impact on Medical Testing, Healthcare 3
... Citing one-time gains due to Hurricane Katrina and other Gulf ... a net loss of nearly $45 million, or 20 cents ... information management services firm reported net income of $105.9 million, ... of 2005, a drop of 29.6 percent. , ,The decrease ...
... visit to the Menomonee Valley, Gov. Jim Doyle ... state budget for the new Wisconsin Venture Center. , ,Doyle ... that will connect entrepreneurs with sources of capital, and serve ... in Wisconsin. , ,The concept was announced in December of ...
... most spending proposals, the devil is in the details and ... Jim Doyle's new Grow Milwaukee package contains several initiatives ... ,The package, which Doyle alluded to in last week's ... economic development, healthcare, and education proposals designed to build on ...
Cached Biology Technology:Doyle proposes $2M for venture capital center 2Grow Milwaukee includes millions for tech funding 2Grow Milwaukee includes millions for tech funding 3
(Date:6/24/2015)... -- The biologics safety testing market is growing at ... include growth of the pharmaceutical and biological industries and ... years, the number of drug approvals in North American ... approved 225 drug applications and Health Canada approved 99. ... accounted for 3,822 of the pharmaceutical and 1,998 ...
(Date:6/24/2015)... June 24, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced that Sharp has selected its ... authentication for its latest flagship smartphone device, the ... 200 million shipments of its fingerprint ID sensor ... strength, scalability and leadership in the biometrics market ...
(Date:6/24/2015)... Biometry authentication provider KeyLemon today announced ... one face in. Logo - ... in, entering the expanding biometric authentication market in ... answer to the password problem. With advanced face ... KeyLemon, one face in allows users to securely ...
Breaking Biology News(10 mins):Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... a 12-year action plan calling for reducing the hypoxia zone ... and there is no evidence that nutrient loading to the ... have identified some of the biophysical and social barriers to ... that a partnership of researchers work closely with farmers to ...
... N.H. A grant to the University of New ... biologists identify an abundant yet largely unknown category of ... functions they play. The National Science Foundation awarded ... Network on eukaryotic biodiversity. The work will apply new ...
... Md. (Nov. 7, 2013)Chronic obstructive pulmonary diseasea health problem ... it progressively harder to breathecan have a dramatic effect ... activities of daily life because of the disease,s fallout ... in these muscle problems. These include loss of fitness ...
Cached Biology News:Researchers suggest plan to address hypoxia in Gulf of Mexico 2Researchers suggest plan to address hypoxia in Gulf of Mexico 3UNH, UC Davis launch network to study environmental microbes 2Vitamin C could ease muscle fatigue in chronic obstructive pulmonary disease patients 2
... S-X media are neutral, porous ... exclusion chromatography of lipophilic polymers ... organic eluents. The beads are ... carbon tetrachloride, dimethylformamide, ketones, aromatics, ...
... Anti-GSTM1 Monoclonal Antibody Epitope: ... [Schistosoma japonicum]. Recommended Storage: ... Aliquot contents and freeze at -20 C ... of freezing and thawing. Centrifuge product if ...
Mouse monoclonal [HYB 232-02] to Protein S ( Abpromise for all tested applications). entrezGeneID: 5627 SwissProtID: P07225...
... unique aptamer microarray services using a ... and sequence design software to suit ... screening of aptamers as drug candidates. ... sequence design, synthesis of standard or ...
Biology Products: